In July 2026, the U.S. Court of Appeals for the Federal Circuit delivered a significant ruling in Wyeth LLC v. AstraZeneca Pharmaceuticals LP, affirming the invalidation of Wyeth’s patent claims for lack of enablement. This decision underscores the stringent requirements for patent specifications, particularly in the realm of pharmaceutical treatments.
Wyeth’s patents, U.S. Patent Nos. 10,603,314 and 10,596,162, pertained to methods for treating non-small cell lung cancer (NSCLC) resistant to standard therapies, utilizing irreversible epidermal growth factor receptor (EGFR) inhibitors. The claims specified administering a “unit dosage” daily to a patient. However, the Federal Circuit found that the patent specifications failed to provide sufficient guidance for determining such dosages without undue experimentation. The court emphasized that the specifications offered only in vitro data and broad dosage ranges, lacking concrete examples or methodologies for translating laboratory findings into effective human treatments. Consequently, the court concluded that the patents did not enable a person skilled in the art to practice the full scope of the claimed invention without extensive, undue experimentation. ([law.justia.com](https://law.justia.com/cases/federal/appellate-courts/cafc/24-2325/24-2325-2026-07-09.html?utm_source=openai))
This ruling aligns with the Supreme Court’s 2023 decision in Amgen Inc. v. Sanofi, which reinforced that a patent must enable the full scope of the claimed invention. The Supreme Court stated, “The more one claims, the more one must enable,” highlighting the necessity for detailed disclosures when broad claims are made. ([en.wikipedia.org](https://en.wikipedia.org/wiki/Amgen_Inc_v._Sanofi?utm_source=openai))
The Wyeth decision serves as a cautionary tale for patent applicants in the pharmaceutical sector. It illustrates the critical importance of providing comprehensive and practical guidance in patent specifications, especially when claiming methods of treatment. Merely presenting in vitro data without clear pathways to clinical application may render patents vulnerable to invalidation for lack of enablement.